2013-09 to Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Researcher, Group Leader
2011-01 to 2012-06 - Hormel Institute, USA - Postdoctoral Researcher
2006-08 to 2013-08 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Associate Researcher
2004-08 to 2006-07 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Postdoctoral Researcher
1994-08 to 2004-08 - Zhengzhou University - Assistant Lecturer, Lecturer
Shanghai May 1st Labor Medal (2021): City Level
First Prize for Anti-tumor Class 1 New Drug EGFR Third Generation Inhibitor ASK120067 Project (2021): City Level
Research
Tumor Pharmacology
A novel strategy for treating oncogene-mutant tumors by targeting tumor microenvironment and synergistically enhancing anti-PD1 immunotherapy, Not mentioned, 2024
From bench to bedside: current development and emerging trend of KRAS-targeted therapy, Not mentioned, 2024
A Novel IRAK4 Inhibitor DW18134 Ameliorates Peritonitis and Inflammatory Bowel Disease, Not mentioned, 2024
Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphoma, Not mentioned, 2024
Design, synthesis and pharmacological evaluation of 2,3-dihydrobenzofuran IRAK4 inhibitors for the treatment of diffuse large B-cell lymphoma, Not mentioned, 2023
Design and Synthesis of 1H-Pyrazolo[3,4-d]pyrimidine Derivatives as Hematopoietic Progenitor Kinase 1 (HPK1) inhibitors, Not mentioned, 2023
Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo, Not mentioned, 2023
Application of deep generative model for design of Pyrrolo2,3-d pyrimidine derivatives as new selective TANK binding kinase 1 (TBK1) inhibitors, Not mentioned, 2023
Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors, Not mentioned, 2023
Design, synthesis and evaluation of (R)-8-((tetrahydrofuran-2-yl)methyl)pyrido[2,3-d]pyrimidin-7-ones as novel selective ACK1 inhibitors to combat acquired resistance to the 3rd-generation EGFR inhibitor, Not mentioned, 2023
Design, synthesis and biological evaluation of KRASG12C-PROTACs as protein degraders, Not mentioned, 2023
18F-Labeled o-aminopyridyl alkynyl radioligands targeting colony-stimulating factor 1 receptor for neuroinflammation imaging, Not mentioned, 2023
Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood-brain barrier and exhibits potent activity against GBM, Not mentioned, 2023
ASK120067 potently suppresses B-cell or T-cell malignancy in vitro and in vivo by inhibiting BTK and ITK, Not mentioned, 2022
LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo, Not mentioned, 2022
Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-GenerationEpidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations, Not mentioned, 2022
Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFR(T790M/C797S) Mutants, Not mentioned, 2022
Discovery of N-(3-bromo-1H-indol-5-yl)-quinazolin-4-amine as an effective molecular skeleton to develop reversible/irreversible pan-HER inhibitors, Not mentioned, 2022
Identification of 1H-pyrazolo3,4-bpyridine derivatives as novel and potent TBK1 inhibitors: design, synthesis, biological evaluation, and molecular docking study, Not mentioned, 2022
ASK120067 (limertinib) Exerts Pre-clinical Anti-tumor Activity by Inhibiting EGFR Exon20 Insertion, Not mentioned, 2022
Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs, Not mentioned, 2021
Discovery and structure - activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors, Not mentioned, 2021
TANK-binding kinase 1 (TBK1): An emerging therapeutic target for drug discovery, Not mentioned, 2021
Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRASG12C inhibitors, Not mentioned, 2021
Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2Hpyrimido[4,5-d][1,3]oxazin-1(4H)-ly)phenyl)acrylamide as potent Bruton’s tyrosine kinase inhibitors, Not mentioned, 2020
Novel Class of Colony-Stimulating Factor 1 Receptor Kinase Inhibitors Based on an o-Aminopyridyl Alkynyl Scaffold as Potential Treatment for Inflammatory Disorders, Not mentioned, 2020
Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88L265P diffuse large B-cell lymphoma, Not mentioned, 2020
2-Oxo-3,4-dihydropyrimido4,5-d pyrimidines as new reversible inhibitors of EGFR C797S(Cys797 to Ser797)mutant, Not mentioned, 2020
Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance, Not mentioned, 2020
Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation, Not mentioned, 2020
Design, synthesis and biological study of potent and covalent HER-2 tyrosine kinase inhibitors with low cytotoxicity in vitro, Not mentioned, 2019
Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFR(L858R/T790M/C797S)), Not mentioned, 2019
Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton’s tyrosine kinase inhibitors, Not mentioned, 2019
Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFRL858R/T790M/C797S, Not mentioned, 2019
C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis, Not mentioned, 2019
DW10075, a novel highly selective inhibitor of vascular endothelial growth factor receptor, exhibits antitumor activities both in vitro and in vivo., Not mentioned, 2016
Discovery of 1,3-Diaryl-pyridones as Potent VEGFR-2 Inhibitors: Design, Synthesis, and Biological Evaluation, Not mentioned, 2016
Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation, Not mentioned, 2016
Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors, Not mentioned, 2016
Design, synthesis and biological evaluation of biphenylurea derivatives as VEGFR-2 kinase inhibitors (II), Not mentioned, 2016
A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties., Not mentioned, 2016
C-5 Substituted Pyrido[2,3-d] pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinica resistance-related EGFRT790M mutant, Not mentioned, 2015
Design, synthesis and biological evaluation of O-linked indoles as VEGFR-2 kinase inhibitors (I), Not mentioned, 2015
Discovery of anilinopyrimidine-based naphthamide derivatives as potent VEGFR-2 inhibitors, Not mentioned, 2015
2,4-Diarylamino-pyrimidines as kinase inhibitors co-targeting IGF1R and EGFR(L858R/T790M), Not mentioned, 2015
Discovery of a New Series of Naphthamides as Potent VEGFR-2 Kinase Inhibitors, Not mentioned
